Article
Immunology
John Hansen, Arnold Yee, Ned Lewis, Se Li, Christine Velicer, Patricia Saddier, Nicola P. Klein
Summary: The study aimed to assess the safety of the nine-valent human papillomavirus vaccine (HPV9) following routine administration. The results showed that there were no new safety concerns identified related to HPV9.
Article
Immunology
Zhuhang Huang, Jianfeng He, Jiali Su, Zhiqiang Ou, Guixiu Liu, Rong Fu, Qiong Shou, Minghuan Zheng, Thomas Group, Alain Luxembourg, Xueyan Liao, Jikai Zhang
Summary: This Phase 3 study aimed to assess the immunogenicity and safety of the qHPV vaccine in Chinese girls aged 9-19 years versus young women aged 20-26 years. The results showed that both age groups developed antibody responses to all vaccine HPV types at Month 7, with similar antibody titers between the two groups. Adverse events were reported after vaccination in both groups, but no vaccine-related serious adverse events were observed. Overall, the 3-dose qHPV vaccination regimen was well tolerated in the study population.
Article
Immunology
John D. Seeger, Kandace L. Amend, Bruce R. Turnbull, Li Zhou, Morgan A. Marks, Christine Velicer, Patricia Saddier
Summary: This study assessed the risk of new onset autoimmune conditions among males receiving the 4-valent human papillomavirus (HPV) vaccine (4vHPV), and the results showed that the incidence of autoimmune conditions among vaccinated males was similar to that among unvaccinated males.
Article
Biotechnology & Applied Microbiology
Suzanne M. Garland, Manjula Anagani, Neerja Bhatla, Sukanta Chatterjee, Sanjay Lalwani, Cecil Ross, Thomas Group, Jianxin Lin, Alain Luxembourg, Anuj Walia, Yingmei Tu
Summary: The quadrivalent and 9-valent human papillomavirus vaccines have shown efficacy, immunogenicity, and safety in clinical trials conducted in India. They induced robust antibody responses and were well tolerated by the participants.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2022)
Article
Immunology
Jamiyah Hassan, Teck-Hock Toh, Selva Kumar Sivapunniam, Ruziaton Hasim, Nor Faizah Ghazali, Sofiah Sulaiman, Mia Tuang Koh, Stephanie Meyer, Myew-Ling Toh, Celine Zocchetti, Claire Vigne, Cesar Mascarenas
Summary: The study conducted in Malaysia among healthy children aged 9-13 found that the immunogenicity and safety profiles of CYD-TDV and quadrivalent HPV vaccines were unaffected when administered concomitantly or sequentially in dengue-seropositive participants. There were no safety concerns identified, and antibody titers for both HPV and dengue were similar between treatment groups.
PEDIATRIC INFECTIOUS DISEASE JOURNAL
(2021)
Article
Biotechnology & Applied Microbiology
Vu Dinh Thiem, Nguyen Dang Quang, Nguyen Hai Tuan, Kyeongmi Cheon, Nancy Gallagher, Alain Luxembourg, Thomas Group, Cyrus Badshah
Summary: This study assessed the immunogenicity and safety of the nine-valent human papillomavirus vaccine in Vietnamese males and females aged 9-26 years. The three-dose vaccine regimen resulted in robust immune responses for all vaccine types, with acceptable seropositivity percentages. The vaccine was well tolerated among the study population from Vietnam.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2021)
Review
Immunology
Mingzhu Li, Chao Zhao, Yun Zhao, Jingran Li, Lihui Wei
Summary: The incidence rate and mortality rate of cervical cancer have been increasing among young women in China. To address this, it is crucial to improve HPV vaccination rates, especially among the younger population. China currently offers five types of HPV vaccines, all of which have undergone clinical trials and have been proven to be safe, effective, and immunogenic in preventing persistent HPV infections and genital precancerous lesions. However, the low vaccination rate in China calls for increased efforts to reduce the incidence and mortality rates of cervical cancer.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Biotechnology & Applied Microbiology
Kandace L. Amend, Bruce Turnbull, Li Zhou, Morgan A. Marks, Christine Velicer, Patricia Saddier, John D. Seeger
Summary: This study assesses the safety of the 4-valent HPV vaccine in males and finds associations with same-day allergic reactions, ear infections, intracranial injury, cellulitis, and concussion. However, other adverse outcomes are determined to be more likely related to activities common in adolescent males rather than the vaccination itself.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2022)
Article
Immunology
Juan J. Hernandez-Aguado, Damian Angel Sanchez Torres, Esther Martinez Lamela, Gema Aguion Galvez, Eva Sanz Espinosa, Almudena Perez Quintanilla, Daniela A. Martinez-Carrillo, Mar Ramirez Mena, Pluvio J. Coronado Martin, Ignacio Zapardiel, Jesus de la Fuente-Valero
Summary: This study examines the effectiveness of the quadrivalent HPV vaccine in reducing HPV infection and cytologic abnormalities in Spain. The results indicate a significant reduction in infection rates and associated cytologic abnormalities in the vaccinated group.
Article
Biotechnology & Applied Microbiology
Yu Hu, Xuejiao Pan, Linzhi Shen, Fuxing Chen, Ying Wang, Hui Liang, Yaping Chen, Huakun Lv
Summary: The study evaluated the reporting rate of adverse events following immunization with the quadrivalent human papillomavirus vaccine in Zhejiang province, and compared it with other vaccines. The most common event reported was fever/redness/induration, and no new or unexpected safety concerns were identified in the analysis.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2021)
Article
Immunology
Jiyeon Kim, Eun-Do Kim, Hae-Sol Shin, Soo Jung Han, Munkhdelger Jamiyansharav, Sang Chul Yoon, Jihei Sara Lee, Kyoung Yul Seo
Summary: Mucosal vaccines, such as the eye mucosa vaccination, have shown to induce strong immune responses and have potential in preventing diseases like influenza, Toxoplasma gondii infection, and hemolytic ure-mic syndrome. This study demonstrated that the HPV vaccine, Cervarix, administered as eyedrops, resulted in significant immune reactions and did not cause inflammation or adverse effects in mice. The findings suggest that Cervarix eyedrop vaccine could be an effective and safe mucosal vaccine against HPV-associated cancers.
Review
Immunology
Andrea Conti, Gaia Broglia, Chiara Sacchi, Fabrizia Risi, Francesco Barone-Adesi, Massimiliano Panella
Summary: Different quadrivalent antimeningococcal vaccine formulations have been developed, but their availability varies and there is a lack of updated systematic review comparing these formulations. We conducted a meta-analysis of 16 studies to evaluate the efficacy and safety of the vaccines. MenACWY-TT showed better efficacy than MenACWY-D and MenACWY-CRM for certain serogroups, while there were no significant differences in efficacy between MenC and MenACWY-TT. No significant safety differences were found between MenACWY-TT and MenC, or among different MenACWY formulations. MenACWY-TT may be preferred to improve vaccination programs and inform future immunization policies.
Article
Biotechnology & Applied Microbiology
Ivette Maldonado, Manuel Plata, Mauricio Gonzalez, Alfonso Correa, Claudia Nossa, Anna R. Giuliano, Elmar A. Joura, Alex Ferenczy, Brigitte M. Ronnett, Mark H. Stoler, Hao Jin Zhou, Amita Joshi, Rituparna Das, Oliver Bautista, Thomas Group, Alain Luxembourg, Alfred Saah, Ulrike Kirsten Buchwald
Summary: This study reports the long-term effectiveness and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine in women and men. The results show that the vaccine is effective in preventing HPV-related diseases in women and men aged 27-45 years.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2022)
Article
Infectious Diseases
Napaporn Chantasrisawad, Watsamon Jantarabenjakul, Suvaporn Anugulruengkitt, Suda Punrin, Kornvika Limsuwun, Panadda Sawangsinth, Chayapa Phasomsap, Jiratchaya Sophonphan, Chitsanu Pancharoen, Thanyawee Puthanakit
Summary: The study showed that the 2-dose rabies pre-exposure prophylaxis regimen produced adequate immune response whether administered on days 0 and 7, or days 0 and 28. 100 children aged 3 to 9 years participated in the study from November 2019 to January 2020.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Immunology
Smita Joshi, Devasena Anantharaman, Richard Muwonge, Neerja Bhatla, Gitika Panicker, Julia Butt, Usha Rani Reddy Poli, Sylla G. Malvi, Pulikkottil O. Esmy, Eric Lucas, Yogesh Verma, Anand Shah, Eric Zomawia, Sharmila Pimple, Kasturi Jayant, Sanjay Hingmire, Aruna Chiwate, Uma Divate, Shachi Vashist, Gauravi Mishra, Radhika Jadhav, Maqsood Siddiqi, Subha Sankaran, Thiraviam Pillai Rameshwari Ammal Kannan, Purnima Kartha, Surendra S. Shastri, Catherine Sauvaget, M. Radhakrishna Pillai, Tim Waterboer, Martin Mueller, Peter Sehr, Elizabeth R. Unger, Rengaswamy Sankaranarayanan, Partha Basu
Summary: The recent WHO recommendation on single-dose HPV vaccine can reduce costs, alleviate supply shortages, and simplify logistics, making it more accessible for low- and middle-income countries. This study examines the long-term immune response and compares it with unvaccinated women, showing sustained immune response in single-dose recipients at 10 years post-vaccination.
Article
Orthopedics
Ronald A. Navarro, Charles C. Lin, Bailey Colli, Lei Qian, In-Lu Amy Liu, Lina S. Sy, Steven J. Jacobsen, Sara Y. Tartof
Summary: This study assessed the impact of influenza vaccination during hospitalization for orthopaedic surgery on postdischarge infection evaluations. The results showed that there was no significant increase in the risk of readmission, emergency department visits, fever, or clinical workups for infection among patients vaccinated during their inpatient stay. However, there was a slightly increased risk of outpatient visits in the 7 days postdischarge.
JOURNAL OF THE AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS
(2022)
Article
Biochemistry & Molecular Biology
Hung Fu Tseng, Bradley K. Ackerson, Yi Luo, Lina S. Sy, Carla A. Talarico, Yun Tian, Katia J. Bruxvoort, Julia E. Tubert, Ana Florea, Jennifer H. Ku, Gina S. Lee, Soon Kyu Choi, Harpreet S. Takhar, Michael Aragones, Lei Qian
Summary: A test-negative case-control analysis using data from a diverse population in California, USA, demonstrates that vaccine efficacy of a three-dose regimen of the mRNA-1273 COVID-19 vaccine is reduced against infection with the Omicron SARS-CoV-2 variant in comparison to Delta, but that efficacy against hospitalization remained high for both variants.
Article
Immunology
Holly C. Groom, Bradley Crane, Allison L. Naleway, Eric Weintraub, Matthew F. Daley, Kris Wain, Mary Beth Kurilo, Rachael Burganowski, Malini B. DeSilva, James G. Donahue, Sungching C. Glenn, Kristin Goddard, Michael L. Jackson, Elyse O. Kharbanda, Ned Lewis, Yingbo Lou, Marlene Lugg, Erica Scotty, Lina S. Sy, Joshua T. B. Williams, Stephanie A. Irving
Summary: This study investigated the data receiving and integration status of eight Vaccine Safety Datalink (VSD) sites, and found that COVID-19 vaccine data can be timely received and integrated, which lays a solid foundation for vaccine safety quality assessments within the VSD.
Letter
Immunology
Bradley Ackerson, Katia Bruxvoort, Lei Qian, Lina S. Sy, Hung Fu Tseng
JOURNAL OF INFECTIOUS DISEASES
(2023)
Article
Immunology
Ana Florea, Lina S. Sy, Lei Qian, Bradley K. Ackerson, Yi Luo, Julia E. Tubert, Gina S. Lee, Jennifer H. Ku, Katia J. Bruxvoort, Carla A. Talarico, Sijia Qiu, Yun Tian, Hung Fu Tseng
Summary: Among immunocompetent adults, the mRNA-1273 booster provides additional protection against SARS-CoV-2 infection and severe COVID-19 disease compared to the 2-dose mRNA-1273 primary series during periods of Delta and Omicron predominance.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Immunology
Stanley Xu, Runxin Huang, Lina S. Sy, Vennis Hong, Sungching C. Glenn, Denison S. Ryan, Kerresa Morrissette, Gabriela Vazquez-Benitez, Jason M. Glanz, Nicola P. Klein, Bruce Fireman, David McClure, Elizabeth G. Liles, Eric S. Weintraub, Hung -Fu Tseng, Lei Qian
Summary: We conducted a large cohort study to evaluate the risk of non-COVID-19 mortality after COVID-19 vaccination. The results showed that the non-COVID-19 mortality rates among COVID-19 vaccinees were lower than those among comparators, and no increased risk was found for non-COVID-19 mortality among recipients of the three COVID-19 vaccines used in the US.
Article
Multidisciplinary Sciences
Hung Fu Tseng, Bradley K. Ackerson, Katia J. Bruxvoort, Lina S. Sy, Julia E. Tubert, Gina S. Lee, Jennifer H. Ku, Ana Florea, Yi Luo, Sijia Qiu, Soon Kyu Choi, Harpreet S. Takhar, Michael Aragones, Yamuna D. Paila, Scott Chavers, Carla A. Talarico, Lei Qian
Summary: This study evaluates the effectiveness of the mRNA-1273 (Moderna) vaccine for Omicron subvariants based on data from the USA. It shows that while effectiveness against infection decreases rapidly after the third and fourth doses, effectiveness against hospitalization remains high. The study also suggests reduced neutralization against omicron BA.4/BA.5 compared to earlier omicron subvariants.
NATURE COMMUNICATIONS
(2023)
Article
Infectious Diseases
Ana Florea, Lina S. Sy, Bradley K. Ackerson, Lei Qian, Yi Luo, Tracy Becerra-Culqui, Gina S. Lee, Yun Tian, Chengyi Zheng, Radha Bathala, Sara Y. Tartof, Laura Campora, Maria Angeles Ceregido, Anastasia Kuznetsova, Jean-Etienne Poirrier, Dominique Rosillon, Laura Valdes, Brigitte Cheuvart, Narcisa Mesaros, Nadia Meyer, Adrienne Guignard, Hung-Fu Tseng
Summary: This study evaluated the risk of congenital anomalies in infants following prenatal vaccination with the Tdap vaccine. The results showed a significantly increased risk of congenital anomalies in certain body systems among vaccinated women. However, these findings may be attributed to improved diagnosis rather than a direct association with the vaccine.
INFECTIOUS DISEASES AND THERAPY
(2023)
Article
Immunology
Kayla E. Hanson, Mona Marin, Matthew F. Daley, Lisa A. Jackson, Lina S. Sy, Nicola P. Klein, Malini B. DeSilva, Lakshmi Panagiotakopoulos, Eric Weintraub, Edward A. Belongia, Huong Q. McLean, Holly C. Groom
Summary: This study aimed to investigate the safety of the measles, mumps, and rubella vaccine (MMR) in adolescents and adults. The results showed that serious adverse events after MMR were rare in this age group, but individuals should be informed about the potential occurrence of local and systemic non-serious adverse events.
Article
Immunology
Jennifer H. Ku, Lina S. Sy, Lei Qian, Bradley K. Ackerson, Yi Luo, Julia E. Tubert, Gina S. Lee, Ana Florea, Katia J. Bruxvoort, Carla A. Talarico, Sijia Qiu, Yun Tian, Hung Fu Tseng
Summary: A study found that the 3-dose mRNA-1273 vaccine series is more effective than the 2-dose series, especially among immunocompromised individuals. The study highlights the importance of completing the 3-dose vaccine series for immunocompromised populations.
Article
Immunology
Bradley Ackerson, Lina S. Sy, Jeff Slezak, Lei Qian, Kristi Reynolds, Runxin Huang, Zendi Solano, William Towner, Sijia Qiu, Sarah R. Simmons, Steven J. Jacobsen, Katia J. Bruxvoort
Summary: This study compared the incidence of immune-mediated diseases, herpes zoster, and anaphylaxis between recipients of HepB-CpG and HepB-alum vaccines. The results showed that there were similar rates of most immune-mediated diseases and herpes zoster between the two groups, except for a slightly higher rate of rheumatoid arthritis. The incidence of anaphylaxis was very low. Therefore, HepB-CpG vaccine does not have significant safety concerns compared to HepB-alum vaccine.
Article
Immunology
Jennifer H. Ku, Lina S. Sy, Lei Qian, Bradley K. Ackerson, Yi Luo, Julia E. Tubert, Gina S. Lee, Ana Florea, Katia J. Bruxvoort, Fagen Xie, Sijia Qiu, Scott Chavers, Carla A. Talarico, Hung Fu Tseng
Summary: We assessed the relative vaccine effectiveness (rVE) of 4 vs. 3 doses of mRNA-1273 against SARS-CoV-2 infection, COVID-19 hospitalization, and death in immunocompetent adults aged >50 years. The adjusted 4 vs. 3-dose rVE for SARS-CoV-2 infection, COVID-19 hospitalization, and COVID-19 hospitalization death were 25.9%, 67.3%, and 72.5%, respectively. The adjusted rVE for SARS-CoV-2 infection ranged from 19.8% to 39.1% across subgroups. The protection provided by four mRNA-1273 doses against COVID-19 outcomes was significant, although rVE varied and declined over time.
Article
Immunology
Ana Florea, Jun Wu, Lei Qian, Bruno Lewin, Lina S. Sy, I-Chun Lin, Jennifer H. Ku, Hung Fu Tseng
Summary: A cohort study found that there may be an increased risk of herpes zoster (HZ) after receiving mRNA COVID-19 vaccines, especially in individuals aged 50 and over without a history of zoster vaccination. The risk of HZ was increased by 1.14 and 1.12 times within 90 days after receiving the second dose of mRNA-1273 and BNT162b2 vaccines, respectively.
EXPERT REVIEW OF VACCINES
(2023)
Article
Multidisciplinary Sciences
Hung Fu Tseng, Bradley K. Ackerson, Lina S. Sy, Julia E. Tubert, Yi Luo, Sijia Qiu, Gina S. Lee, Katia J. Bruxvoort, Jennifer H. Ku, Ana Florea, Harpreet S. Takhar, Radha Bathala, Cindy Ke Zhou, Daina B. Esposito, Morgan A. Marks, Evan J. Anderson, Carla A. Talarico, Lei Qian
Summary: The bivalent mRNA-1273 COVID-19 vaccine was found to be highly effective in preventing hospitalization for COVID-19, medically attended SARS-CoV-2 infection, and COVID-19 hospital death. The relative vaccine effectiveness against hospitalization for COVID-19 was 70.3%, and the protection provided by the bivalent booster lasted for at least 3 months.
NATURE COMMUNICATIONS
(2023)
Article
Public, Environmental & Occupational Health
Stanley Xu, Vennis Hong, Lina S. Sy, Katia J. Bruxvoort, Bruno Lewin, Bing Han, Kimberly J. Holmquist, Lei Qian
Summary: This study examined the risk factors for not completing a 2-dose primary series of mRNA COVID-19 vaccination. The results showed that age, gender, race/ethnicity, health insurance, and pre-vaccination health status were all associated with noncompletion. These findings can inform the development of strategies to improve vaccination coverage and completion rates.
JMIR PUBLIC HEALTH AND SURVEILLANCE
(2023)
